The Gb Sciences Inc (OTCMKTS:GBLX) stock has been one of the notable movers this week and yesterday, the stock was in focus among many investors as it ended the days with gains of as much as 16%.
The stock came into focus among investors on Tuesday after it announced that it got positive proof of concept data with regards to its CBD based product that is meant for suppressing the effects of cytokine release syndrome in patients suffering from COVID 19. It goes without saying that the announcement from the company was a significant one and the rally in the stock is hence quite understandable.
In this regard, it is also necessary to note that after the details of the proof of concept data was revealed to the company, Gb Sciences also changed its provisional patent application to a non-provisional one back on August 18 this year.
The original patent had been titled “CANNABINOID-CONTAINING COMPLEX MIXTURES FOR THE TREATMENT OF CYTOKINE RELEASE SYNDROME WHILE PRESERVING KEY ANTI-VIRAL IMMUNE REACTIONS.” Considering the gains made by the stock yesterday, it could be in focus today as well and investors could consider keeping an eye on it.